Quantcast

Industry news that matters to you.  Learn more

Using Biomarkers to Identify and Treat Schizophrenia

In the current online issue of PLoS ONE, researchers at the University of California, San Diego School of Medicine say they have identified a set of laboratory-based biomarkers that can be useful for understanding brain-based abnormalities in schizophrenia. The measurements, known as endophenotypes, could ultimately be a boon to clinicians who sometimes struggle to recognize and treat the complex and confounding mental disorder.

Caris Life Sciences Launches Caris Target Now Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary

Caris Life Sciences®, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced the launch of Caris Target Now™ Select, an advanced, evidence-based molecular profiling service for patients with non-small cell lung cancer (NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition, the company has enhanced the original Caris Target Now comprehensive molecular profiling service offering for all solid tumors.

New Data Indicate Pressure BioSciences’ Novel Technology Platform Offers Great Promise to the Areas of Biomarker Discovery and Drug Development

Pressure BioSciences, Inc. (Nasdaq:PBIO) (“PBI” and the “Company”) announced recently that data supporting important advantages of PBI’s powerful and enabling Pressure Cycling Technology (“PCT”) Platform were presented last week at the 56th Annual Meeting of the Biophysical Society in San Diego, CA and this week at the 8th Annual US Human Proteomic Organization (“HUPO”) Conference in San Francisco, CA.

Biomarker Commons Named Personalized Medicine World Conference (PMWC) Media Partner

The 4th Personalized Medicine World Conference (PMWC) 2012 will be held in Mountain View, California from January 23rd-24th at Silicon Valley’s Computer History Museum. PMWC brings together the thought-leaders in business, government, healthcare-delivery, research and technology for one information-rich, two-day conference.

Lupus Experts Gather at the FDA to Explore Potential for Biomarkers to Accelerate Clinical Trials

Biomarkers, potential indicators to monitor disease progress and treatment success, are among the most challenging and critical areas of lupus research according representatives of industry, academia, government and advocacy attending a U.S. Food and Drug Administration workshop this week. The meeting was convened to focus on the development of biomarkers to predict acute worsening of disease, called a flare, and their potential for accelerating lupus clinical trials and new drug approvals.